A Phase 2 interventional study of Eculizumab in Stage V Chronic Kidney Disease, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 15 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-03.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objective:
To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
First submitted before Alexion Pharmaceuticals, Inc. became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of prior exposure to HLA (human leukocyte antigen):
Exclusion Criteria:
Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion. Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days. Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days.
Drug: Eculizumab
Also known as: Soliris
Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation
Results are reported for post-transplantation treatment failure and composite endpoints, defined as the occurrence of biopsy-proven acute antibody-mediated rejection (AMR), graft loss, death, or loss to follow-up (including discontinuation) in the first 9 weeks post transplantation. The diagnosis of acute AMR (occurring within the first 9 weeks post transplantation) was based on kidney allograft dysfunction and a biopsy performed due to suspected rejection, proteinuria, increased serum creatinine, or acute tubular necrosis. Treatment failure was the occurrence of at least 1 of the composite endpoint components by Week 9 post transplantation. A participant experiencing multiple events was only counted once for the composite endpoint.
Time frame: Baseline, Week 9
Cumulative Incidence Function (CIF) Of Other Adverse Events (AEs) Of Interest At Month 12
Specific analyses of other AEs of interest that occurred at Month 12 included cumulative incidence of clinically significant infection (CSI); post-transplant lymphoproliferative disease (PTLD); malignancies; biopsy-proven acute cellular rejection (ACR) of any grade meeting Banff 2007 criteria; allograft loss for reasons other than AMR. CSIs were defined as infections (confirmed by culture, biopsy, genomic, or serologic findings) that required hospitalization or anti-infective treatment, or otherwise deemed significant by the Investigator. CSI subcategories of interest included cytomegalovirus (CMV) disease; BK virus disease; encapsulated bacterial infection; fungal infections; aspergillus infections. Results are reported as CIF, where a larger CIF indicates a higher incidence of an AE, and were calculated using Statistical Analysis System software and macro CIF. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline, Month 12
Participants That Developed Severe ACR (Other AE Of Interest) At Month 12
This outcome measure focuses on the other AE of interest, severe ACR, which occurred at Month 12. It pertains specifically to the number of participants who developed severe ACR that did not respond to thymoglobulin or other lymphocyte-depleting agents. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Baseline, Month 12
| Milestone | Eculizumab |
|---|---|
| Started | 80 |
| Received at least 1 dose of study drug | 80 |
| Completed | 60 |
| Not completed | 20 |
| Withdrew: Death | 6 |
| Withdrew: Adverse event | 6 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Graft loss | 2 |
| Withdrew: Renal transplantectomy | 1 |
| Withdrew: Returned to chronic dialysis | 1 |
| Withdrew: Terminal chronic kidney dysfunction | 1 |
Results are reported for post-transplantation treatment failure and composite endpoints, defined as the occurrence of biopsy-proven acute antibody-mediated rejection (AMR), graft loss, death, or loss to follow-up (including discontinuation) in the first 9 weeks post transplantation. The diagnosis of acute AMR (occurring within the first 9 weeks post transplantation) was based on kidney allograft dysfunction and a biopsy performed due to suspected rejection, proteinuria, increased serum creatinine, or acute tubular necrosis. Treatment failure was the occurrence of at least 1 of the composite endpoint components by Week 9 post transplantation. A participant experiencing multiple events was only counted once for the composite endpoint.
| Participants | Eculizumab |
|---|---|
| Treatment Failure - Yes | 7 |
| Treatment Failure - No | 73 |
| Biopsy-proven Acute AMR | 3 |
| Graft Loss | 4 |
| Death | 1 |
| Lost to Follow-up (Including Discontinuation) | 1 |
Specific analyses of other AEs of interest that occurred at Month 12 included cumulative incidence of clinically significant infection (CSI); post-transplant lymphoproliferative disease (PTLD); malignancies; biopsy-proven acute cellular rejection (ACR) of any grade meeting Banff 2007 criteria; allograft loss for reasons other than AMR. CSIs were defined as infections (confirmed by culture, biopsy, genomic, or serologic findings) that required hospitalization or anti-infective treatment, or otherwise deemed significant by the Investigator. CSI subcategories of interest included cytomegalovirus (CMV) disease; BK virus disease; encapsulated bacterial infection; fungal infections; aspergillus infections. Results are reported as CIF, where a larger CIF indicates a higher incidence of an AE, and were calculated using Statistical Analysis System software and macro CIF. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
| Proportion of Adverse Events | Eculizumab |
|---|---|
| Confirmed CSI | 0.7989 (0.69 to 0.87) |
| CMV Infection | 0.2994 (0.20 to 0.40) |
| BK Virus Infection | 0.1536 (0.08 to 0.24) |
| Encapsulated Bacterial Infection | 0.1642 (0.09 to 0.25) |
| Fungal Infection | 0.1287 (0.07 to 0.21) |
| Aspergillus Infection | 0 (0 to 0) |
| PTLD | 0.0264 (0.00 to 0.08) |
| Malignancies | 0.0264 (0.00 to 0.08) |
| Biopsy-proven ACR | 0.0375 (0.01 to 0.10) |
| Allograft Loss For Reasons Other Than AMR | 0.1132 (0.06 to 0.19) |
This outcome measure focuses on the other AE of interest, severe ACR, which occurred at Month 12. It pertains specifically to the number of participants who developed severe ACR that did not respond to thymoglobulin or other lymphocyte-depleting agents. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Eculizumab |
|---|---|
| Participants That Developed Severe ACR (Other AE Of Interest) At Month 12 | 3 |
Collected over Adverse event data were collected beginning on the day of transplantation, Day 0, through 12 months post transplantation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 6/80 (7.5%) | 70/80 (87.5%) | 80/80 (100%) |
| Event | Eculizumab |
|---|---|
| Kidney transplant rejectionImmune system disorders | 25/80 |
| Acute kidney injuryRenal and urinary disorders | 12/80 |
| Delayed graft functionInjury, poisoning and procedural complications | 10/80 |
| PyelonephritisInfections and infestations | 7/80 |
| Blood creatinine increasedInvestigations | 6/80 |
| Bacterial pyelonephritisInfections and infestations | 5/80 |
| Cytomegalovirus infectionInfections and infestations | 5/80 |
| PneumoniaInfections and infestations | 5/80 |
| HaematuriaRenal and urinary disorders | 5/80 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 5/80 |
| Event | Eculizumab |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 51/80 |
| DiarrhoeaGastrointestinal disorders | 37/80 |
| Urinary tract infectionInfections and infestations | 32/80 |
| Oedema peripheralGeneral disorders | 31/80 |
| HypertensionVascular disorders | 31/80 |
| LeukopeniaBlood and lymphatic system disorders | 30/80 |
| NauseaGastrointestinal disorders | 25/80 |
| HyperkalaemiaMetabolism and nutrition disorders | 23/80 |
| Kidney transplant rejectionImmune system disorders | 22/80 |
| HeadacheNervous system disorders | 22/80 |
Safety Population: enrolled participants who received at least 1 dose of eculizumab.
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 50.7 ± 11.26 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 48 |
| Male | 32 |
| Race/Ethnicity, Customized(Participants) | Eculizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 5 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 59 |
| Unknown or Not Reported | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2012 to primary completion in Jun 2015, 33 months.
Results were first posted in May 2019, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →